Business Wire

Process Systems Enterprise: APM Forum 2019 focus on digitalisation for the process industries

Share

Digital design and digital operations were the key focus at the 2019 Advanced Process Modelling (APM) Forum in London, where leading process industry organisations presented on how advanced modelling technologies are helping to create value in applications ranging from accelerating time-to-market of new pharmaceuticals to maximising production from multiple oil & gas processing sites simultaneously.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190403005719/en/

Prof. Costas Pantelides describes the benefits of digital process design and operations based on the ...

Prof. Costas Pantelides describes the benefits of digital process design and operations based on the deep process knowledge embedded in high-fidelity models (Photo: Business Wire)

Introducing the event, Prof. Costas Pantelides, MD of conference host Process Systems Enterprise (PSE), said that technologies that combine prior knowledge, in the form of physics-based models, with laboratory or plant data, or use accurate nonlinear surrogate models derived from large-scale physics-based models, now provide unprecedented opportunities for exploring the design decision space and incorporating deep process knowledge in operational decision systems.

Keynote speaker Bob Docherty, Strategic Lead for Digital Design at Pfizer, presented a global vision for digitalisation in the pharma industry that enables a level of clarity in manufacturing processes never available before. Mathias Oppelt, head of simulation at Siemens, described how Siemens is bringing to market intelligent digital operations tools, capable of generating value daily, that incorporate high-fidelity process models using PSE’s gPROMS technology, as well as integrated engineering systems capable of generating process digital twins automatically during the engineering phase.

In the Formulated Products track, presenters from GSK, Pfizer, Eli Lilly, AstraZeneca, BMS, UCB and Novo Nordisk described a range of applications built on PSE’s gPROMS FormulatedProducts modelling environment: end-to-end digital design applications to enhance drug substance and drug product R&D and manufacture, the increasing application of mechanistic models in manufacturing for control scheme development, process monitoring and soft-sensing, and the use of digital twins for optimising fermentation processes. PSE and Centre of Excellence partners NIZO launched the new gPROMS Food capability for modelling food products and processes.

In the Energy & Chemicals track, integrated petrochemicals manufacturer SCG Chemicals described the use of digital twins for rapid-response operator decision support for their vinyl chloride monomer (VCM) operations. DNV GL showed their COSSMOS digital design environment for integrated ship systems, and RWTH Aachen described how optimisation technology now enables simultaneous design of process, equipment and working fluid in organic Rankine cycles and CO2 absorption processes. Siemens demonstrated a digital twin for integrated wells-to-facilities optimisation of oilfield production embedded in a Siemens XHQ dashboard, for operations room decision support.

PSE launched major new capabilities including enhanced digital design capabilities in the forthcoming gPROMS 6 modelling platform, where high-performance computing (HPC) capabilities now enable execution of complex models on massively parallel clusters to allow rapid and effective exploration of large decision spaces, and gPROMS Properties, PSE’s new properties and advanced thermodynamics platform. The new gPROMS Digital Applications Platform for building, testing and deploying robust and efficient digital applications within plant automation or management systems was demonstrated using a nonlinear model predictive controller for polymer production. Also announced were the new gPROMS Web Applications System for delivering models to ‘non-modelling’ users across the organisation via web interfaces, and the new gPROMS ProcessBuilder which allows seamless workflows from steady-state to dynamic modelling within the same environment.

Says Pantelides, “several strands of core technology are now coming together to accelerate digital design and to bring exciting new capabilities to operations. High-fidelity process models are at the heart of this. It’s all moving very rapidly”.

Contact information

Kate Burness +44-20-8563-0888
k.burness@psenterprise.com
Editors: www.psenterprise.com/news/pr190403

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CESTPress release

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who

Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include

Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente

Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CESTPress release

Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe

Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CESTPress release

Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu